Skip to main content
Erschienen in: Rheumatology International 6/2012

01.06.2012 | Original Article

Increased myeloperoxidase plasma levels in rheumatoid arthritis

verfasst von: Raissa Maria Sampaio Neves Fernandes, Neusa Pereira da Silva, Emília Inoue Sato

Erschienen in: Rheumatology International | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

High myeloperoxidase (MPO) serum levels have been shown in several inflammatory diseases, including rheumatoid arthritis (RA). However, the correlation between MPO levels and disease activity in RA patients is still controversial. The aim of the study was to determine MPO plasma levels in RA patients and to investigate potential correlations between MPO levels and disease activity and treatment. MPO plasma levels were measured by ELISA according the manufacturer’s instructions. Disease activity was measured by DAS28 ESR and DAS28 CRP scores, and patients were classified into 4 groups: group 1 DAS28 < 2.6; group 2: 2.6 ≤ DAS28 ≤ 3.2; group 3: 3.2 < DAS28 ≤ 5.1 and group 4: DAS28 > 5.1. Rheumatoid factor (RF) was measured by latex agglutination test, and anti-cyclic citrullinated peptide (anti-CCP) antibodies were detected by ELISA with a commercial kit. Fifty-seven female RA patients (mean age: 46.02 ± 13.47 years, mean disease duration: 115.77 ± 99.44 months) and sixty gender- and age-paired healthy controls were included. Mean MPO plasma levels were significantly higher in patients than in controls (72.27 pM vs. 40.78 pM, P = 0.007). RF was found in 59.6% and anti-CCP in 80.7% of the RA patients. No significant difference in MPO levels was seen among the four RA disease activity groups. We did not find significant correlation between MPO levels and disease activity as measured by DAS28 score. In conclusion, we observed significantly higher MPO plasma levels in RA patients when compared to healthy controls. However, we did not find correlation between MPO plasma level and disease activity.
Literatur
1.
Zurück zum Zitat Turesson C, Matteson EL (2006) Genetics of rheumatoid arthritis. Mayo Clin Proc 81(1):94–101PubMedCrossRef Turesson C, Matteson EL (2006) Genetics of rheumatoid arthritis. Mayo Clin Proc 81(1):94–101PubMedCrossRef
2.
3.
Zurück zum Zitat Lefkowitz DL, Mills K, Lefkowitz SS, Bollen A, Moguilevsky N (1995) Neutrophil-macrophage interaction: a paradigm for chronic inflammation. Med Hypotheses 44:58–62PubMedCrossRef Lefkowitz DL, Mills K, Lefkowitz SS, Bollen A, Moguilevsky N (1995) Neutrophil-macrophage interaction: a paradigm for chronic inflammation. Med Hypotheses 44:58–62PubMedCrossRef
4.
Zurück zum Zitat Lefkowitz DL, Lefkowitz SS (2001) Macrophage-neutrophil interaction: a paradigm for chronic inflammation revisited. Immunol Cell Biol 79:502–506PubMedCrossRef Lefkowitz DL, Lefkowitz SS (2001) Macrophage-neutrophil interaction: a paradigm for chronic inflammation revisited. Immunol Cell Biol 79:502–506PubMedCrossRef
5.
Zurück zum Zitat Brennan M-L, Penn MS, Van Lent F et al (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595–1604PubMedCrossRef Brennan M-L, Penn MS, Van Lent F et al (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595–1604PubMedCrossRef
6.
Zurück zum Zitat Torsteinsdóttir I, Hakansson L, Hällgren R, Gudbjörnsson B, Arvidson NG, Venge P (1999) Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 38:1249–1254CrossRef Torsteinsdóttir I, Hakansson L, Hällgren R, Gudbjörnsson B, Arvidson NG, Venge P (1999) Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 38:1249–1254CrossRef
7.
Zurück zum Zitat Milovanovic M, Nilsson E, Järemo P (2004) Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 343:237–240PubMedCrossRef Milovanovic M, Nilsson E, Järemo P (2004) Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 343:237–240PubMedCrossRef
8.
Zurück zum Zitat Minohara M, Matsuoka T, Li W et al (2006) Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity. J Neuroimmunol 178:156–160PubMedCrossRef Minohara M, Matsuoka T, Li W et al (2006) Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity. J Neuroimmunol 178:156–160PubMedCrossRef
9.
Zurück zum Zitat Baskol G, Demir H, Baskol M et al (2006) Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 24:307–311PubMedCrossRef Baskol G, Demir H, Baskol M et al (2006) Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 24:307–311PubMedCrossRef
10.
Zurück zum Zitat Accardo-Palumbo A, Triolo G, Carbone MC et al (2000) Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet`s disease. Clin Exp Rheumatol 18:495–498PubMed Accardo-Palumbo A, Triolo G, Carbone MC et al (2000) Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet`s disease. Clin Exp Rheumatol 18:495–498PubMed
11.
Zurück zum Zitat Baldus S, Heeschen C, Meinertz T et al (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440–1445PubMedCrossRef Baldus S, Heeschen C, Meinertz T et al (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440–1445PubMedCrossRef
12.
Zurück zum Zitat Arnet FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef Arnet FC, Edworthy SM, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef
13.
Zurück zum Zitat Prevoo ML, Van Gestel AM, Van′t Hof MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL (1996) Remission in a prospective study of patients with rheumatoid arthritis. American rheumatism association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 35:1101–1105PubMedCrossRef Prevoo ML, Van Gestel AM, Van′t Hof MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL (1996) Remission in a prospective study of patients with rheumatoid arthritis. American rheumatism association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 35:1101–1105PubMedCrossRef
14.
Zurück zum Zitat Prevoo MLL, Van′t Hof MA, Van Leeuwen MA, Pute LB, Van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo MLL, Van′t Hof MA, Van Leeuwen MA, Pute LB, Van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
15.
Zurück zum Zitat Van Gestel AM, Haagsma CJ, van Riel PLCM (1998) Validation of rheumatoid arthritis improvement criteria that includes simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef Van Gestel AM, Haagsma CJ, van Riel PLCM (1998) Validation of rheumatoid arthritis improvement criteria that includes simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef
16.
Zurück zum Zitat Costa D, Moutinho L, Lima JLFC, Fernandes E (2006) Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. Biol. Pharm. Bull 29:1659–1670PubMedCrossRef Costa D, Moutinho L, Lima JLFC, Fernandes E (2006) Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. Biol. Pharm. Bull 29:1659–1670PubMedCrossRef
17.
Zurück zum Zitat Wildfeuer A (1984) Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol 43:23–26PubMed Wildfeuer A (1984) Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol 43:23–26PubMed
18.
Zurück zum Zitat Lau D, Mollnau H, Eiserich JP et al (2005) Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci 102(2):431–436PubMedCrossRef Lau D, Mollnau H, Eiserich JP et al (2005) Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci 102(2):431–436PubMedCrossRef
19.
Zurück zum Zitat Telles RW, Ferreira GA, Silva NP, Sato EI (2010) Increased plasma myeloperoxidase levels in systemic lupus erythematosus. Rheumatol Int 30:779–784PubMedCrossRef Telles RW, Ferreira GA, Silva NP, Sato EI (2010) Increased plasma myeloperoxidase levels in systemic lupus erythematosus. Rheumatol Int 30:779–784PubMedCrossRef
Metadaten
Titel
Increased myeloperoxidase plasma levels in rheumatoid arthritis
verfasst von
Raissa Maria Sampaio Neves Fernandes
Neusa Pereira da Silva
Emília Inoue Sato
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 6/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-1810-5

Weitere Artikel der Ausgabe 6/2012

Rheumatology International 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.